TIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis.
Antimicrobial resistance: Q&A with CARB-X about the fight against AMR
BackgroundCombating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is an industry alliance to support research and development projects in AMR. Since its inception in 2016, CARB-X has supported 114 R&D projects across 14 countries, leading to 18 projects advancing into or completing clinical trials. EBM talked to CARB-X Executive Director Kevin Outterson.
UK Government invests millions into new health data service
Latest NewsUK focuses on digital health research: 600 british pounds (US$764m) for new data platform according to the five recommendations of the Sudlow report.
Reinforcement for Angelini Ventures
AppointmentsDr Regina Hodits joined Angelini Ventures, the VC arm of Angelini Industries, in April as the new Managing Director. She will be based in Germany and lead the company’s international biotech investment strategy with focus Biotech AI and therapeutics.
Swedish TIRmed Pharma raises 4,3m€ against atopic dermatitis
Latest NewsTIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis.
Menarini and ERBC collaborate
Latest NewsFrench ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development.
Switzerland needs more efforts in biomedicine
Latest NewsIn February 2025, the Federal Office of Public Health (FOPH) announced that the Masterplan in Biomedicine will be discontinued. This sends a troubling signal at a time of growing protectionism and potential trade conflicts. While other nations are actively collaborating with industry to secure the future of their pharmaceutical sectors, Switzerland is abandoning the only federal initiative aimed at improving conditions for biomedical research. The organisation scienceindustries calls for a renewed effort by the government to develop a new master plan.
Morphosys’ antibody still shining – for J&J
Latest NewsThe case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game and has now full ownership while expanding the indications further.
Revolutionising Oral Drug Delivery
AssociationsNovoArc GmbH, an Austrian biotech startup and BIOTECH AUSTRIA member, develops lipid-based formulations to enable the oral delivery of drugs that currently require injection. Its innovative approach paves the way for more convenient and effective treatments.
MoonLake in US$500m debt deal with Hercules Capital
Latest NewsSwiss MoonLake Immunotherapeutics AG has secured up to US$500m in non-dilutive financing from life sciences debt specialist Hercules Capital to finance the potential 2027 launch of sonelokimab in hidradenitis suppurativa and clinical trials of the IL-17 dimerisation blocker in palmoplantar pustulosis and other inflammatory indications.
Knowledge-based bioeonomy – reloaded
OpinionBiotechnology provides the necessary toolbox, ranging from energy-saving biocatalysts for the chemical industry to climate-friendly production of animal feed and food proteins for more resilience, microbial recovery of rare critical materials, to the production of pharmaceutically active ingredients.